Tristel PLC is an AIM-listed manufacturer of infection prevention, contamination control and hygiene products with a consistent record of revenue, profit and dividend growth. It is one of only a few businesses worldwide that specialises in infection prevention, and has four principal activities:
• Medical instrument disinfection under the Tristel brand
• Hospital surface disinfection under the Cache brand
• Cleanroom, pharma and lab hygiene under the Crystel brand
• Infection prevention in animal healthcare under the Anistel brand
The Tristel story began in 1993 when the founding shareholders developed a proprietary chlorine dioxide formulation to be used for the disinfection of flexible endoscopes to replace glutaraldehyde, which was at the time used worldwide for the disinfection of heat-sensitive medical instruments but was known to be toxic.
During the course of the following decade, Tristel gradually captured significant market share in the United Kingdom hospital market. In June 2005 Tristel plc was listed on the London Stock Exchange AIM market.
In 2012 Tristel created its Anistel brand for the animal healthcare market and commenced the manufacture and sale of contamination control products under the Crystel brand for the pharmaceutical and personal care industry. The Group’s most recent major new product initiative is to enter the global hospital surface disinfection marketplace with its Cache Collection.
Following its IPO Tristel embarked upon overseas expansion establishing distributors within Continental Europe, the Middle and the Far East and established direct operations in New Zealand, Australia, Hong Kong, China, Malaysia, Russia and throughout Europe. Tristel considers itself to be a well-recognised force in the global infection control industry.
The Investor Centre was last updated on 27/10/2020. The information contained within it is disclosed in accordance with AIM Rule 26. The Company is subject to the UK City Code on Takeovers and Mergers.